Haloperidol (Haldol)

Antipsychotic - First-Generation (Typical)

Overview

Haloperidol, marketed as Haldol, is a first-generation (typical) antipsychotic used to treat schizophrenia, Tourette syndrome, acute psychosis, agitation, and other psychiatric conditions. It is available in oral, intramuscular (IM), intravenous (IV), and long-acting injectable (decanoate) forms. Haloperidol is highly effective for positive symptoms of psychosis but has a significant risk of extrapyramidal side effects (EPS) and tardive dyskinesia, necessitating careful monitoring. Its rapid onset makes it a preferred choice for acute agitation.

Mechanism of Action

Haloperidol is a potent dopamine D2 receptor antagonist, with additional antagonism at alpha-1 adrenergic and serotonin 5-HT2 receptors at higher doses. Its strong D2 receptor blockade is responsible for its antipsychotic effects but also contributes to a high risk of EPS. The alpha-1 antagonism can cause orthostatic hypotension, while 5-HT2 effects are minimal compared to atypical antipsychotics. Haloperidol’s receptor profile underlies its efficacy in psychosis and its side effect burden.

Indications

  • Schizophrenia: Adults and adolescents (13-17 years).
  • Tourette Syndrome: Control of tics and vocal utterances in adults and children (3-12 years).
  • Behavioral Disorders in Children: Severe combative or explosive behavior (ages 3-12 years).
  • Hyperactivity in Children: Short-term treatment of hyperactivity with impulsivity or aggression (ages 3-12 years).
  • Acute Agitation: Management in psychiatric emergencies or delirium.
  • Bipolar Mania: Acute treatment of manic episodes.
  • Chemotherapy-Induced Nausea: Effective for nausea and vomiting.
  • Intractable Hiccups: Used for persistent hiccups.

Dosing and Administration

Indication Starting Dose Therapeutic Range Maximum Dose
Schizophrenia (Adults, Oral) 0.5-2 mg 2-3 times daily 2-20 mg/day 100 mg/day
Schizophrenia (Adolescents, Oral) 0.5-1 mg 2-3 times daily 2-15 mg/day 30 mg/day
Schizophrenia (IM, Short-Acting) 2-5 mg every 4-8 hours 2-20 mg/day 20 mg/day
Schizophrenia (IM, Decanoate) 10-20 times daily oral dose every 4 weeks 50-200 mg every 4 weeks 450 mg every 4 weeks
Tourette Syndrome (Adults, Oral) 0.5-2 mg 2-3 times daily 2-6 mg/day 30 mg/day
Tourette Syndrome (Children, Oral) 0.05-0.075 mg/kg/day 1-4 mg/day Not specified
Acute Agitation (IM, Adults) 2-5 mg every 4-8 hours 2-20 mg/day 20 mg/day
Behavioral Disorders (Children, Oral) 0.05-0.075 mg/kg/day 0.5-6 mg/day Not specified
  • Elderly: Start at 0.5-1 mg 2-3 times daily; titrate slowly due to increased EPS and sedation risks.
  • Hepatic Impairment: No adjustment needed; monitor for side effects.
  • Renal Impairment: No adjustment needed; use caution in severe impairment.
  • Pregnancy: Category C; risk of neonatal withdrawal; use only if benefits outweigh risks.
  • Breastfeeding: Present in breast milk; monitor infant for sedation or developmental delays.
Clinical Pearl: Haloperidol IM is typically dosed at bedtime for acute agitation due to rapid onset. For decanoate, maintain oral dosing for 1-2 weeks after the first injection to ensure steady-state levels.

Pharmacokinetics

Parameter Details
Absorption Oral bioavailability 60-70%; peak plasma levels in 2-6 hours (oral), 10-20 minutes (IM).
Metabolism Hepatic via CYP3A4, CYP2D6, and glucuronidation; no active metabolites.
Half-Life 14-26 hours (oral), 20.7 hours (IM), 3 weeks (decanoate).
Excretion Urine (40%, 1% unchanged); feces (60%).
Clinical Pearl: Haloperidol’s long half-life with decanoate allows monthly dosing, improving adherence, but requires careful monitoring for EPS accumulation.

Side Effects

  • Extrapyramidal Symptoms: Akathisia (15%), parkinsonism (20%), dystonia (10%).
  • Central Nervous System: Sedation (10%), headache (5%), insomnia (5%).
  • Cardiovascular: Orthostatic hypotension (5%), tachycardia (3%).
  • Other: Dry mouth (4%), constipation (3%).

Data from clinical trials (Janssen, 2023).

  • Tardive Dyskinesia: Risk increases with long-term use; monitor for involuntary movements.
  • Neuroleptic Malignant Syndrome (NMS): Rare; symptoms include fever, rigidity, altered mental status.
  • QT Prolongation: Risk with IV use or high doses; monitor ECG in at-risk patients.
  • Seizures: May lower seizure threshold; use cautiously in epilepsy.
  • Hyperprolactinemia: Can cause galactorrhea, amenorrhea, or sexual dysfunction.
Clinical Pearl: Haloperidol’s high EPS risk requires prophylactic anticholinergics (e.g., benztropine) in many patients, especially at doses above 5 mg/day.

Interactions

  • CYP3A4 Inhibitors (e.g., ketoconazole): Increase haloperidol levels; may require dose reduction.
  • CYP3A4 Inducers (e.g., carbamazepine): Decrease haloperidol levels; may require dose increase.
  • QT-Prolonging Drugs (e.g., amiodarone): Increased risk of QT prolongation; monitor ECG.
  • Antihypertensives: Enhanced hypotensive effects due to alpha-1 blockade; monitor BP.
  • CNS Depressants (e.g., alcohol, benzodiazepines): Additive sedation; caution advised.
Clinical Pearl: Avoid grapefruit juice (CYP3A4 inhibitor) while on haloperidol to prevent increased levels and EPS risk. Monitor for enhanced sedation when combining with other CNS depressants.

Contraindications and Warnings

  • Hypersensitivity to haloperidol.
  • Severe CNS depression or coma.
  • Parkinson’s disease or dementia with Lewy bodies (relative contraindication).
  • Increased Mortality in Elderly: Black box warning for dementia-related psychosis; avoid in elderly with dementia.
  • EPS and Tardive Dyskinesia: High risk; monitor closely, especially with long-term use.
  • QT Prolongation: Avoid in patients with known QT prolongation or on QT-prolonging drugs.
  • Orthostatic Hypotension: Risk during initial titration; titrate slowly in elderly.
  • Seizures: May lower seizure threshold; use cautiously in epilepsy.

Evidence and Guidelines

  • Schizophrenia: 60-70% response rate for positive symptoms at 2-20 mg/day; comparable to other typical antipsychotics (Cochrane Database Syst Rev, 2015).
  • Acute Agitation: Effective for rapid tranquilization in emergency settings (Cochrane Database Syst Rev, 2017).
  • Tourette Syndrome: Reduced tic severity by 50-70% at 2-6 mg/day (J Psychopharmacol, 2021).
  • APA (2020): Recommended for schizophrenia and acute agitation; use with caution due to EPS risk.
  • NICE (2014): Suggested for schizophrenia and Tourette syndrome; monitor for movement disorders.
  • FDA Labeling: Warning for increased mortality in elderly with dementia and QT prolongation risk.

Monitoring Parameters

  • Movement Disorders: Assess for EPS and tardive dyskinesia at each visit using standardized scales (e.g., AIMS).
  • Cardiovascular: Monitor BP during titration; ECG if using IV or in patients with cardiac risk factors.
  • Neurologic: Monitor for signs of NMS or seizures, especially in high-risk patients.
  • Metabolic: Check weight and glucose periodically, though less critical than with atypicals.
  • Liver Function: Monitor LFTs in patients with hepatic impairment.

Patient Education

  • What to Expect: Improvement in symptoms may take 1-2 weeks; muscle stiffness or restlessness are common.
  • Managing Side Effects: Report muscle spasms or tremors to your doctor; rise slowly to avoid dizziness.
  • When to Seek Help: Contact your doctor for fever, severe stiffness, irregular heartbeat, or involuntary movements.
  • Avoid Abrupt Stopping: Taper with your doctor to avoid withdrawal or symptom rebound.